Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 689

1.

The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.

Kadija S, Stefanovic A, Jeremic K, Radojevic MM, Nikolic L, Markovic I, Atanackovic J.

Int J Gynecol Cancer. 2012 Feb;22(2):238-44. doi: 10.1097/IGC.0b013e318234f852.

PMID:
22214964
2.

[Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma].

Wang MJ, Qi J, Wang H, Li XX, Wei BJ, Fu C, Gao J, Han BB.

Zhonghua Zhong Liu Za Zhi. 2011 Jul;33(7):540-3. Chinese.

PMID:
22093635
3.

[The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].

Dong L, Chang XH, Ye X, Zhu LR, Zhao Y, Tian L, Cheng HY, Li XP, Zhang H, Liao QP, Fu TY, Cheng YX, Cui H.

Zhonghua Fu Chan Ke Za Zhi. 2008 Dec;43(12):931-6. Chinese.

PMID:
19134334
4.

Serum HE4 as a useful biomarker in discriminating ovarian cancer from benign pelvic disease.

Zheng H, Gao Y.

Int J Gynecol Cancer. 2012 Jul;22(6):1000-5. doi: 10.1097/IGC.0b013e318249bee7.

PMID:
22426406
5.

Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.

Karlsen MA, Sandhu N, Høgdall C, Christensen IJ, Nedergaard L, Lundvall L, Engelholm SA, Pedersen AT, Hartwell D, Lydolph M, Laursen IA, Høgdall EV.

Gynecol Oncol. 2012 Nov;127(2):379-83. doi: 10.1016/j.ygyno.2012.07.106. Epub 2012 Jul 24.

PMID:
22835718
6.

HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm.

Van Gorp T, Cadron I, Despierre E, Daemen A, Leunen K, Amant F, Timmerman D, De Moor B, Vergote I.

Br J Cancer. 2011 Mar 1;104(5):863-70. doi: 10.1038/sj.bjc.6606092. Epub 2011 Feb 8.

7.

Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome.

Sandri MT, Bottari F, Franchi D, Boveri S, Candiani M, Ronzoni S, Peiretti M, Radice D, Passerini R, Sideri M.

Gynecol Oncol. 2013 Feb;128(2):233-8. doi: 10.1016/j.ygyno.2012.11.026. Epub 2012 Nov 28.

PMID:
23200911
8.

A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses.

Anton C, Carvalho FM, Oliveira EI, Maciel GA, Baracat EC, Carvalho JP.

Clinics (Sao Paulo). 2012;67(5):437-41.

9.

The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.

Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, Bast RC Jr.

Gynecol Oncol. 2008 Feb;108(2):402-8. Epub 2007 Dec 3.

PMID:
18061248
10.

Human epididymis protein 4 (HE4) as a serum tumor biomarker in patients with ovarian carcinoma.

Chang X, Ye X, Dong L, Cheng H, Cheng Y, Zhu L, Liao Q, Zhao Y, Tian L, Fu T, Chen J, Cui H.

Int J Gynecol Cancer. 2011 Jul;21(5):852-8. doi: 10.1097/IGC.0b013e31821a3726.

PMID:
21633297
11.

The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?

Montagnana M, Danese E, Ruzzenente O, Bresciani V, Nuzzo T, Gelati M, Salvagno GL, Franchi M, Lippi G, Guidi GC.

Clin Chem Lab Med. 2011 Mar;49(3):521-5. doi: 10.1515/CCLM.2011.075. Epub 2011 Feb 3.

PMID:
21288178
12.

The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass.

Chan KK, Chen CA, Nam JH, Ochiai K, Wilailak S, Choon AT, Sabaratnam S, Hebbar S, Sickan J, Schodin BA, Sumpaico WW.

Gynecol Oncol. 2013 Feb;128(2):239-44. doi: 10.1016/j.ygyno.2012.09.034. Epub 2012 Oct 10.

PMID:
23063998
13.

The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass.

Montagnana M, Lippi G, Ruzzenente O, Bresciani V, Danese E, Scevarolli S, Salvagno GL, Giudici S, Franchi M, Guidi GC.

J Clin Lab Anal. 2009;23(5):331-5. doi: 10.1002/jcla.20340.

PMID:
19774626
14.

Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis.

Li F, Tie R, Chang K, Wang F, Deng S, Lu W, Yu L, Chen M.

BMC Cancer. 2012 Jun 19;12:258. doi: 10.1186/1471-2407-12-258.

15.

[Measurement of serum human epididymis secretory protein 4 combined with CA125 assay in differential diagnosis of endometriosis cyst and ovarian benign and malignant tumors].

Liu YN, Ye X, Cheng HY, Cheng YX, Fu TY, Chen J, Chang XH, Cui H.

Zhonghua Fu Chan Ke Za Zhi. 2010 May;45(5):363-6. Chinese.

PMID:
20646446
16.

Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases.

Park Y, Lee JH, Hong DJ, Lee EY, Kim HS.

Clin Biochem. 2011 Jul;44(10-11):884-8. doi: 10.1016/j.clinbiochem.2011.04.011. Epub 2011 Apr 22.

PMID:
21549107
17.

Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age.

Kondalsamy-Chennakesavan S, Hackethal A, Bowtell D; Australian Ovarian Cancer Study Group, Obermair A.

Gynecol Oncol. 2013 Jun;129(3):467-71. doi: 10.1016/j.ygyno.2013.03.001. Epub 2013 Mar 13.

PMID:
23500084
18.

Evaluation of HE4 as an extrabiomarker to CA125 to improve detection of ovarian carcinoma: is it time for a step forward?

Azzam AZ, Hashad DI, Kamel NA.

Arch Gynecol Obstet. 2013 Jul;288(1):167-72. doi: 10.1007/s00404-013-2722-2. Epub 2013 Jan 30.

PMID:
23361457
19.

Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses.

Chen X, Zhou H, Chen R, He J, Wang Y, Huang L, Sun L, Duan C, Luo X, Yan H.

Clin Chim Acta. 2015 Feb 2;440:57-63. doi: 10.1016/j.cca.2014.11.013. Epub 2014 Nov 15.

PMID:
25447698
20.

Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response.

Hamed EO, Ahmed H, Sedeek OB, Mohammed AM, Abd-Alla AA, Abdel Ghaffar HM.

Diagn Pathol. 2013 Jan 23;8:11. doi: 10.1186/1746-1596-8-11.

Supplemental Content

Support Center